PT4587429T - Compostos de oxoisoindolinil piperidina-2,6-diona substituídos - Google Patents
Compostos de oxoisoindolinil piperidina-2,6-diona substituídosInfo
- Publication number
- PT4587429T PT4587429T PT247827116T PT24782711T PT4587429T PT 4587429 T PT4587429 T PT 4587429T PT 247827116 T PT247827116 T PT 247827116T PT 24782711 T PT24782711 T PT 24782711T PT 4587429 T PT4587429 T PT 4587429T
- Authority
- PT
- Portugal
- Prior art keywords
- oxoisoindolinyl
- piperidine
- compounds substituted
- dione compounds
- dione
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363582266P | 2023-09-13 | 2023-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT4587429T true PT4587429T (pt) | 2026-03-20 |
Family
ID=92931770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT247827116T PT4587429T (pt) | 2023-09-13 | 2024-09-12 | Compostos de oxoisoindolinil piperidina-2,6-diona substituídos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20250084056A1 (pt) |
| EP (1) | EP4587429B1 (pt) |
| JP (1) | JP7808733B2 (pt) |
| KR (1) | KR20250068738A (pt) |
| AR (1) | AR133800A1 (pt) |
| AU (1) | AU2024342875A1 (pt) |
| CO (1) | CO2026002534A2 (pt) |
| DK (1) | DK4587429T3 (pt) |
| FI (1) | FI4587429T3 (pt) |
| HR (1) | HRP20260405T1 (pt) |
| IL (1) | IL327007A (pt) |
| LT (1) | LT4587429T (pt) |
| MA (1) | MA72090B1 (pt) |
| MX (1) | MX2026002570A (pt) |
| PT (1) | PT4587429T (pt) |
| RS (1) | RS67970B1 (pt) |
| SM (1) | SMT202600147T1 (pt) |
| TW (1) | TW202525792A (pt) |
| WO (1) | WO2025059245A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120441535B (zh) * | 2025-07-08 | 2025-09-30 | 苏州国匡医药科技有限公司 | 一种含炔基的gspt1降解剂及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| TWI382974B (zh) | 2005-12-20 | 2013-01-21 | 英塞特公司 | 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物 |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CN101932325B (zh) | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PT3023438T (pt) | 2009-09-03 | 2020-05-08 | Merck Sharp & Dohme | Anticorpos anti-gitr |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| EP2949670B1 (en) | 2009-12-10 | 2019-02-27 | F. Hoffmann-La Roche AG | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| SMT201900074T1 (it) | 2010-05-04 | 2019-02-28 | Five Prime Therapeutics Inc | Anticorpi che legano csf1r |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| NO2694640T3 (pt) | 2011-04-15 | 2018-03-17 | ||
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| EP2791174B1 (en) | 2011-12-15 | 2018-02-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| CN104093740B (zh) | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN104684582A (zh) | 2012-08-31 | 2015-06-03 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2019040109A1 (en) | 2017-08-21 | 2019-02-28 | Celgene Corporation | PROCESSES FOR THE PREPARATION OF (S) -TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE |
| US20240261274A1 (en) | 2021-01-13 | 2024-08-08 | Monte Rosa Therapeutics, Inc. | Treatment of myc-driven cancers with gspt1 degraders |
| US20240408093A1 (en) | 2021-10-04 | 2024-12-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| WO2023069720A1 (en) | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
-
2024
- 2024-09-12 WO PCT/US2024/046299 patent/WO2025059245A1/en active Pending
- 2024-09-12 SM SM20260147T patent/SMT202600147T1/it unknown
- 2024-09-12 HR HRP20260405TT patent/HRP20260405T1/hr unknown
- 2024-09-12 EP EP24782711.6A patent/EP4587429B1/en active Active
- 2024-09-12 FI FIEP24782711.6T patent/FI4587429T3/fi active
- 2024-09-12 US US18/882,822 patent/US20250084056A1/en active Pending
- 2024-09-12 AR ARP240102427A patent/AR133800A1/es unknown
- 2024-09-12 DK DK24782711.6T patent/DK4587429T3/da active
- 2024-09-12 KR KR1020257012489A patent/KR20250068738A/ko active Pending
- 2024-09-12 IL IL327007A patent/IL327007A/en unknown
- 2024-09-12 AU AU2024342875A patent/AU2024342875A1/en active Pending
- 2024-09-12 RS RS20260381A patent/RS67970B1/sr unknown
- 2024-09-12 PT PT247827116T patent/PT4587429T/pt unknown
- 2024-09-12 LT LTEPPCT/US2024/046299T patent/LT4587429T/lt unknown
- 2024-09-12 TW TW113134636A patent/TW202525792A/zh unknown
- 2024-09-12 MA MA72090A patent/MA72090B1/fr unknown
- 2024-09-12 JP JP2025528339A patent/JP7808733B2/ja active Active
-
2026
- 2026-02-27 CO CONC2026/0002534A patent/CO2026002534A2/es unknown
- 2026-03-04 MX MX2026002570A patent/MX2026002570A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4587429A1 (en) | 2025-07-23 |
| JP2026500094A (ja) | 2026-01-06 |
| RS67970B1 (sr) | 2026-04-30 |
| CO2026002534A2 (es) | 2026-03-16 |
| DK4587429T3 (da) | 2026-03-30 |
| AU2024342875A1 (en) | 2026-04-30 |
| WO2025059245A1 (en) | 2025-03-20 |
| JP7808733B2 (ja) | 2026-01-29 |
| IL327007A (en) | 2026-05-01 |
| KR20250068738A (ko) | 2025-05-16 |
| US20250084056A1 (en) | 2025-03-13 |
| LT4587429T (lt) | 2026-03-25 |
| AR133800A1 (es) | 2025-11-05 |
| MA72090B1 (fr) | 2026-03-31 |
| EP4587429B1 (en) | 2026-02-18 |
| MX2026002570A (es) | 2026-04-01 |
| FI4587429T3 (fi) | 2026-03-24 |
| TW202525792A (zh) | 2025-07-01 |
| SMT202600147T1 (it) | 2026-05-12 |
| HRP20260405T1 (hr) | 2026-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3577110T3 (pl) | Związki podstawione 8-oksetan-3-ylo-3,8-diazabicyklo[3.2.1]oktan-3-ylem jako inhibitory hiv | |
| EP4121045A4 (en) | CRYSTALLINE NORPSILOCIN COMPOUNDS | |
| EP4536656A4 (en) | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS | |
| SI4055021T1 (sl) | Heterociklične spojine, ki inhibirajo rip1 | |
| IL310528A (en) | Pyrazolopyridinone compounds | |
| LT4084779T (lt) | 1-(4-brom-5-(1-etil-7-(metilamino)-2-okso-1,2-dihidro-1,6-naftiridin-3-il) -2- fluorfenil)-3-fenilkarbamido kompozicijos | |
| DK3054927T3 (da) | Formuleringer af (s)-3-(4-((4-morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion | |
| HUE058998T2 (hu) | Heteroaril vegyületek, mint kináz inhibitorok | |
| DK4320112T3 (da) | Pyridinylsubstituerede oxoisoindolinforbindelser | |
| DK3911631T3 (da) | Hidtil ukendte, substituerede sulfonylureaderivater | |
| CL2020000449S1 (es) | Herramienta de encuadernación. | |
| EP4143199C0 (en) | NUCLEOTIDE PROMEDICINAL COMPOUNDS | |
| DK4229056T3 (da) | Triazolpyridinylforbindelser som kinasehæmmere | |
| DK4587429T3 (da) | Substituerede oxoisoindolinylpiperidin-2,6-dionforbindelser | |
| MA52891A (fr) | Dérivés aza-indoliques utilisés comme inhibiteurs de rho-kinase | |
| IL325422A (en) | A substituted piperidine-2,6-dione oxoisoindolinyl compound as an anticancer agent | |
| IL326828A (en) | Piperidine-2,6-dione azatidinyl oxoisoindolinyl substituted compounds | |
| EP4291180A4 (en) | Crystalline 5-methoxy-dipropyl tryptamine compounds | |
| EP4360809A4 (en) | NAIL GUN | |
| EP4151632A4 (en) | 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative | |
| EP4487626A4 (en) | TIME ADVANCE SHIFT CONFIGURATION | |
| EP4289832A4 (en) | Pyrimidine derivative | |
| CA3304009A1 (en) | Substituted oxoisoindolinyl piperidine-2,6-dione compounds | |
| HK40128683A (zh) | 取代的氧代异吲哚啉基哌啶-2，6-二酮化合物 | |
| PT4038149T (pt) | Compostos anti-incrustação |